Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ...
Clinical Cancer Research 23 (8), 1920-1928
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
MD Burstein, A Tsimelzon, GM Poage, KR Covington, A Contreras, ...
Clinical Cancer Research 21 (7), 1688-1698
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ...
Clinical Cancer Research 22 (18), 4585-4593
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
PF Robbins, SH Kassim, TLN Tran, JS Crystal, RA Morgan, SA Feldman, ...
Clinical Cancer Research 21 (5), 1019-1027
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
M Freeman-Keller, Y Kim, H Cronin, A Richards, G Gibney, JS Weber
Clinical Cancer Research 22 (4), 886-894
Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
TY Seiwert, Z Zuo, MK Keck, A Khattri, CS Pedamallu, T Stricker, C Brown, ...
Clinical Cancer Research 21 (3), 632-641
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
A Patnaik, SP Kang, D Rasco, KP Papadopoulos, J Elassaiss-Schaap, ...
Clinical Cancer Research 21 (19), 4286-4293
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
S Kato, A Goodman, V Walavalkar, DA Barkauskas, A Sharabi, ...
Clinical Cancer Research 23 (15), 4242-4250
JC Dudley, MT Lin, DT Le, JR Eshleman
Clinical Cancer Research 22 (4), 813-820
GL Beatty, WL Gladney
Clinical Cancer Research 21 (4), 687-692
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
T Mok, YL Wu, JS Lee, CJ Yu, V Sriuranpong, J Sandoval-Tan, G Ladrera, ...
Clinical Cancer Research 21 (14), 3196-3203
J Ren, X Liu, C Fang, S Jiang, CH June, Y Zhao
Clinical Cancer Research 23 (9), 2255-2266
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
AA Azad, SV Volik, AW Wyatt, A Haegert, S Le Bihan, RH Bell, ...
Clinical Cancer Research 21 (10), 2315-2324
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
P Ballard, JWT Yates, Z Yang, DW Kim, JCH Yang, M Cantarini, K Pickup, ...
Clinical Cancer Research 22 (20), 5130-5140
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
G Kim, G Ison, AE McKee, H Zhang, S Tang, T Gwise, R Sridhara, E Lee, ...
Clinical Cancer Research 21 (19), 4257-4261
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
MJ Niederst, H Hu, HE Mulvey, EL Lockerman, AR Garcia, Z Piotrowska, ...
Clinical Cancer Research 21 (17), 3924-3933
JPB O'Connor, CJ Rose, JC Waterton, RAD Carano, GJM Parker, ...
Clinical Cancer Research 21 (2), 249-257
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
K Ota, K Azuma, A Kawahara, S Hattori, E Iwama, J Tanizaki, T Harada, ...
Clinical Cancer Research 21 (17), 4014-4021
E White, JM Mehnert, CS Chan
Clinical Cancer Research 21 (22), 5037-5046
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
A Martens, K Wistuba-Hamprecht, MG Foppen, J Yuan, MA Postow, ...
Clinical Cancer Research 22 (12), 2908-2918
1 - 20